vs

Side-by-side financial comparison of LTC PROPERTIES INC (LTC) and VERACYTE, INC. (VCYT). Click either name above to swap in a different company.

VERACYTE, INC. is the larger business by last-quarter revenue ($140.6M vs $84.3M, roughly 1.7× LTC PROPERTIES INC). LTC PROPERTIES INC runs the higher net margin — 123.0% vs 29.3%, a 93.7% gap on every dollar of revenue. On growth, LTC PROPERTIES INC posted the faster year-over-year revenue change (60.3% vs 18.5%). LTC PROPERTIES INC produced more free cash flow last quarter ($128.7M vs $48.8M). Over the past eight quarters, LTC PROPERTIES INC's revenue compounded faster (28.1% CAGR vs 20.5%).

LTC Properties Inc is a U.S.-based real estate investment trust (REIT) that owns, finances, and manages seniors housing and healthcare-related real estate assets. Its core portfolio includes assisted living facilities, skilled nursing properties, memory care centers, and independent living communities for senior care and healthcare service operators.

Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.

LTC vs VCYT — Head-to-Head

Bigger by revenue
VCYT
VCYT
1.7× larger
VCYT
$140.6M
$84.3M
LTC
Growing faster (revenue YoY)
LTC
LTC
+41.8% gap
LTC
60.3%
18.5%
VCYT
Higher net margin
LTC
LTC
93.7% more per $
LTC
123.0%
29.3%
VCYT
More free cash flow
LTC
LTC
$79.9M more FCF
LTC
$128.7M
$48.8M
VCYT
Faster 2-yr revenue CAGR
LTC
LTC
Annualised
LTC
28.1%
20.5%
VCYT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LTC
LTC
VCYT
VCYT
Revenue
$84.3M
$140.6M
Net Profit
$103.7M
$41.1M
Gross Margin
72.5%
Operating Margin
26.4%
Net Margin
123.0%
29.3%
Revenue YoY
60.3%
18.5%
Net Profit YoY
429.1%
704.8%
EPS (diluted)
$2.19
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LTC
LTC
VCYT
VCYT
Q4 25
$84.3M
$140.6M
Q3 25
$69.3M
$131.9M
Q2 25
$60.2M
$130.2M
Q1 25
$49.0M
$114.5M
Q4 24
$52.6M
$118.6M
Q3 24
$55.8M
$115.9M
Q2 24
$50.1M
$114.4M
Q1 24
$51.4M
$96.8M
Net Profit
LTC
LTC
VCYT
VCYT
Q4 25
$103.7M
$41.1M
Q3 25
$-20.0M
$19.1M
Q2 25
$15.1M
$-980.0K
Q1 25
$20.7M
$7.0M
Q4 24
$19.6M
$5.1M
Q3 24
$29.4M
$15.2M
Q2 24
$19.4M
$5.7M
Q1 24
$24.2M
$-1.9M
Gross Margin
LTC
LTC
VCYT
VCYT
Q4 25
72.5%
Q3 25
69.2%
Q2 25
69.0%
Q1 25
69.5%
Q4 24
66.4%
Q3 24
68.2%
Q2 24
68.1%
Q1 24
64.5%
Operating Margin
LTC
LTC
VCYT
VCYT
Q4 25
26.4%
Q3 25
71.9%
17.4%
Q2 25
80.5%
-4.0%
Q1 25
37.8%
2.5%
Q4 24
3.5%
Q3 24
95.5%
10.4%
Q2 24
38.0%
4.0%
Q1 24
47.3%
-4.8%
Net Margin
LTC
LTC
VCYT
VCYT
Q4 25
123.0%
29.3%
Q3 25
-28.9%
14.5%
Q2 25
25.1%
-0.8%
Q1 25
42.2%
6.2%
Q4 24
37.3%
4.3%
Q3 24
52.6%
13.1%
Q2 24
38.6%
5.0%
Q1 24
47.2%
-1.9%
EPS (diluted)
LTC
LTC
VCYT
VCYT
Q4 25
$2.19
$0.50
Q3 25
$-0.44
$0.24
Q2 25
$0.32
$-0.01
Q1 25
$0.45
$0.09
Q4 24
$0.38
$0.07
Q3 24
$0.66
$0.19
Q2 24
$0.44
$0.07
Q1 24
$0.56
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LTC
LTC
VCYT
VCYT
Cash + ST InvestmentsLiquidity on hand
$14.4M
$362.6M
Total DebtLower is stronger
$842.2M
Stockholders' EquityBook value
$1.1B
$1.3B
Total Assets
$2.1B
$1.4B
Debt / EquityLower = less leverage
0.78×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LTC
LTC
VCYT
VCYT
Q4 25
$14.4M
$362.6M
Q3 25
$17.9M
$315.6M
Q2 25
$7.6M
$219.5M
Q1 25
$23.3M
$186.1M
Q4 24
$9.4M
$239.1M
Q3 24
$35.0M
$274.1M
Q2 24
$6.2M
$235.9M
Q1 24
$9.0M
$209.2M
Total Debt
LTC
LTC
VCYT
VCYT
Q4 25
$842.2M
Q3 25
$944.5M
Q2 25
$696.5M
Q1 25
$682.2M
Q4 24
$684.6M
Q3 24
$785.3M
Q2 24
$861.0M
Q1 24
$860.2M
Stockholders' Equity
LTC
LTC
VCYT
VCYT
Q4 25
$1.1B
$1.3B
Q3 25
$957.9M
$1.3B
Q2 25
$957.5M
$1.2B
Q1 25
$961.9M
$1.2B
Q4 24
$960.6M
$1.2B
Q3 24
$947.8M
$1.2B
Q2 24
$889.1M
$1.1B
Q1 24
$886.2M
$1.1B
Total Assets
LTC
LTC
VCYT
VCYT
Q4 25
$2.1B
$1.4B
Q3 25
$2.0B
$1.4B
Q2 25
$1.8B
$1.3B
Q1 25
$1.8B
$1.3B
Q4 24
$1.8B
$1.3B
Q3 24
$1.9B
$1.3B
Q2 24
$1.9B
$1.2B
Q1 24
$1.8B
$1.2B
Debt / Equity
LTC
LTC
VCYT
VCYT
Q4 25
0.78×
Q3 25
0.99×
Q2 25
0.73×
Q1 25
0.71×
Q4 24
0.71×
Q3 24
0.83×
Q2 24
0.97×
Q1 24
0.97×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LTC
LTC
VCYT
VCYT
Operating Cash FlowLast quarter
$136.0M
$52.6M
Free Cash FlowOCF − Capex
$128.7M
$48.8M
FCF MarginFCF / Revenue
152.7%
34.7%
Capex IntensityCapex / Revenue
8.6%
2.7%
Cash ConversionOCF / Net Profit
1.31×
1.28×
TTM Free Cash FlowTrailing 4 quarters
$220.1M
$126.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LTC
LTC
VCYT
VCYT
Q4 25
$136.0M
$52.6M
Q3 25
$38.4M
$44.8M
Q2 25
$30.0M
$33.6M
Q1 25
$29.6M
$5.4M
Q4 24
$125.9M
$24.5M
Q3 24
$34.0M
$30.0M
Q2 24
$37.0M
$29.6M
Q1 24
$21.1M
$-9.0M
Free Cash Flow
LTC
LTC
VCYT
VCYT
Q4 25
$128.7M
$48.8M
Q3 25
$34.3M
$42.0M
Q2 25
$28.9M
$32.3M
Q1 25
$28.2M
$3.5M
Q4 24
$112.2M
$20.4M
Q3 24
$27.7M
$27.7M
Q2 24
$34.7M
$26.8M
Q1 24
$19.7M
$-11.1M
FCF Margin
LTC
LTC
VCYT
VCYT
Q4 25
152.7%
34.7%
Q3 25
49.4%
31.8%
Q2 25
47.9%
24.8%
Q1 25
57.6%
3.1%
Q4 24
213.4%
17.2%
Q3 24
49.7%
23.9%
Q2 24
69.1%
23.4%
Q1 24
38.4%
-11.5%
Capex Intensity
LTC
LTC
VCYT
VCYT
Q4 25
8.6%
2.7%
Q3 25
6.0%
2.1%
Q2 25
1.9%
1.0%
Q1 25
2.7%
1.6%
Q4 24
26.0%
3.5%
Q3 24
11.2%
1.9%
Q2 24
4.6%
2.4%
Q1 24
2.6%
2.2%
Cash Conversion
LTC
LTC
VCYT
VCYT
Q4 25
1.31×
1.28×
Q3 25
2.34×
Q2 25
1.99×
Q1 25
1.43×
0.76×
Q4 24
6.43×
4.80×
Q3 24
1.16×
1.98×
Q2 24
1.91×
5.16×
Q1 24
0.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LTC
LTC

Seniors Housing Operating Portfolio Segment$72.1M86%
Other$12.2M14%

VCYT
VCYT

Testing$135.8M97%
Products$3.8M3%
Biopharmaceutical And Other$686.0K0%

Related Comparisons